Set Text Size: A A A

Retina Associates of New York Now Has Own "Ambulatory Surgery Center"

The Retina Associates of New York has officially opened its newly constructed “Ambulatory Surgery Center.” Located next to our New York medical office, it features two fully equipped state-of-the-art operating rooms, as well as up to date pre-op and post-op areas designed for the highest quality patient care. Relatives and friends are invited to wait in an elegant marble lobby with comfortable seating and a friendly staff. The driving force behind this remarkable achievement of a private set-up has been Dr. Ben Z. Cohen himself, whose untiring efforts, along with the cooperation of our doctors and determination of our Project Manager Lynn Renee Cohen, Ph.D., has led to the realization of this dream. So what’s in it for the patient? Leading edge surgical technology and the opportunity to stay within our facility during the entire diagnostic and treatment process. No more referrals or arduous trips to other surgical establishments. One more step towards providing you the best possible care.

Dr. "Jeff" Lends a Helping Hand in Phillippines

Dr. Jeffrey Paccione, fondly known as “Doctor Jeff”, recently returned from a well-accomplished medical mission in the Philippines. He was, as a Retinal Surgeon, part of a team of prominent ophthalmologists associated with the Manhattan Eye, Ear and Throat Hospital that went to the Far-East on a medical cum surgical ophthalmic mission to provide care to the underprivileged sections of society. The host for the mission was the Angeles University, Philippines. When we spoke to Dr. Paccione about the mission, he said, “It was a great experience in a beautiful country with extremely nice and warm-hearted people. The program was well executed and I am more than eager to go back and do whatever little I can to help those lovely, but at the same time needy people out there!”


New Drug Provides Greater Hope for 'Age-Related Macular Degeneration'

Since the FDA approved the new drug “Lucentis”* for the treatment of the “WET” form of Age-Related Macular Degeneration (AMD), Retina Associates of New York has been, and continues to be, involved in research related to Lucentis and other new treatment options.

For the past several years, Dr. Wald has partnered with major pharmaceutical companies to serve as a clinical site for investigative therapies and the prevention/treatment of conditions such as Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME) and Central Retinal Vein Occlusion (CRVO). While Dr. Wald screens patients for participation in the studies, highly trained technicians track data that the pharmaceutical companies compile and formulate into results. For more information on these studies, as well as patient enrollment, please contact Ms. Nancy Lo (Study Coordinator) at 212-772-0600.

*The generic name of Lucentis is Ramibizumab, a monoclonal anti-body that acts by blocking VEGF (Vascular Endothelial Growth Factor). VEGF is responsible for the growth of fragile new blood vessels underneath the Retina that can leak blood and fluid, causing a profound decrease in vision. Lucentis has been proven to actually improve the condition in many cases, and most often prevent further progress of the disorder. For more information on the drug, you may kindly visit